Contact Us

Center for Breakthrough Medicines Now Provides a Clinically Tested Adherent Manufacturing Platform for AAV Production

April 12, 2023

CBM is the Exclusive CDMO Provider of an iCellis 500-based Adeno-Associated Virus (AAV) Adherent Platform developed by the Gene Therapy Program at the University of Pennsylvania

King of Prussia, PA — April 11, 2023The Center for Breakthrough Medicines (CBM), a contract development and manufacturing organization (CDMO) dedicated to addressing critical challenges associated with the commercialization of cell and gene therapies, has completed a successful technology transfer of the University of Pennsylvania Gene Therapy Program’s (GTP) adherent cell manufacturing platform for producing Adeno-Associated Virus (AAV) gene therapies. As GTP’s exclusive CDMO partner, CBM clients will have immediate access to the adherent platform for AAV vector manufacturing, enabling rapid acceleration of AAV assets from discovery to the clinic.

Comprehensive and scalable, the GTP-developed platform has been well characterized and can be used to quickly manufacture high-quality advanced AAV gene therapies. The manufacturing platform has been used to manufacture 100 successful production scale batches and production runs for four clinical phase programs. With limited process development required and materials ready to go, the manufacturing platform may enable clinical candidate selection to Tox in as little as four months and clinical candidate selection to GMP in as little as six months.

In addition, the GTP-developed platform helps to accelerate development via advanced assays and analytics, onsite testing, reduced sample requirements, and reduced testing turn-around times. The platform’s manufacturing process is applicable across multiple AAV serotypes and genes of therapeutic product development interest. Additionally, its downstream process has an average recovery of 30% and results in greater than 80% full capsids by analytical ultracentrifuge analysis and can pool up to three upstream runs into a single downstream harvest with a typical yield of 4.8E16 total GC at harvest.

“As the exclusive CDMO provider of the GTP-developed platform, CBM is able to provide its clients the option of a well-characterized adherent AAV platform to advance their programs from discovery to first-in-human studies safely and rapidly, with less risk and expense,” said Jennifer Manning, SVP of Global Strategic Partnerships at CBM. “The platform, combined with CBM’s manufacturing expertise and state-of-the-art, high throughput cGMP suites, as well as on-site experts , provides innovator companies the critical elements required to efficiently translate lifesaving therapies from bench to bedside.”

About The Center for Breakthrough Medicines (CBM)

Center for Breakthrough Medicines (CBM) is a purpose-built and patient-driven, cell and gene therapy contract development and manufacturing organization (CDMO) uniquely positioned to enable pharma and biotech companies to develop, test, and manufacture life-saving therapies on a global scale. Ideally located in the heart of Philadelphia’s Cellicon Valley, CBM has assembled the most accomplished cell and gene therapy experts in the world, armed with cutting-edge and innovative technologies, to offer scalable, end-to-end, best-in-class services from pre-clinical through commercial, including process development, plasmid DNA, vector manufacturing, cell banking, cell processing, and a full suite of complementary and standalone testing and analytical capabilities.


For more information, contact:
Center for Breakthrough Medicines
Keith Bowermaster, APR, CCMP

Contact Us Now